In a significant leap forward for inherited retinal disease (IRD) treatment, an 11-year-old girl in the UK has become the first patient in the country to receive a novel gene therapy for Bardet-Biedl Syndrome (BBS), a rare genetic condition that causes progressive vision loss and can lead to blindness by early adulthood. This groundbreaking procedure, performed at St Helier Hospital in Sutton, marks a pivotal moment for patients and families grappling with IRDs, offering renewed hope for preserving sight.
A New Horizon for IRD Treatment
Catherine L'Estrange, from North Acton, London, was diagnosed with BBS as a baby. BBS is a complex inherited disorder caused by mutations in one of at least 20 different genes, affecting approximately one in 100,000 births in the UK. Beyond severe vision loss, which typically progresses to blindness in the late teens or early twenties, BBS can also manifest with kidney problems, learning difficulties, obesity, and sometimes extra fingers or toes.
The gene therapy Catherine received specifically targets mutations in the BBS10 gene, which accounts for over 20% of BBS cases. Developed by biotechnology company MeiraGTx, the treatment involves a delicate, hour-long surgical procedure where healthy copies of the BBS10 gene are injected directly into the retina, the light-sensitive tissue at the back of the eye, after the vitreous jelly is removed. The aim is to halt the degeneration of retinal cells that leads to blindness in BBS patients.
This procedure makes Catherine only the second patient in the world to receive this specific gene therapy for BBS10, following a 17-year-old Canadian patient treated at the same hospital in August 2025. Her father, Reverend Timothy L'Estrange, expressed both surprise and delight, noting that they had been told such a treatment was many years away and likely to arrive after Catherine had already lost her sight.
Broader Implications for Inherited Retinal Diseases
The success and continued development of gene therapies like this one underscore a rapidly evolving landscape in ophthalmology. The eye's unique structure, being small, compartmentalized, and relatively immune-privileged, makes it an ideal target for localized gene delivery, minimizing systemic side effects.
While this particular therapy is new, gene therapy for IRDs is not entirely unprecedented. The approval of voretigene neparvovec-rzyl (Luxturna) in 2017 for RPE65-mediated retinal dystrophy was a landmark achievement, demonstrating the potential for durable and safe gene replacement therapy. Luxturna, which provides a functional copy of the RPE65 gene, has shown significant improvements in visual acuity and light sensitivity for patients with certain forms of Leber congenital amaurosis (LCA) and early-onset retinitis pigmentosa. Recent studies have highlighted the profound impact of Luxturna, with some children experiencing restored sight and improved visual pathways.
The Path Forward
Experts anticipate that if Catherine's treatment is successful, her sight will be stabilized, and there is even potential for improvement. While full results will take months to years to assess, initial responses in similar treatments have shown improved vision in low-light conditions. Catherine herself expressed hope that the treatment will allow her to continue reading, one of her favorite hobbies.
This pioneering treatment for BBS10 is a testament to the relentless progress in gene therapy research. It signifies not only a potential breakthrough for Bardet-Biedl Syndrome but also fuels optimism for the development of treatments for other complex IRDs. As research continues to advance, with ongoing clinical trials for various conditions like retinitis pigmentosa, Stargardt disease, and Usher syndrome, the future looks increasingly brighter for individuals affected by inherited retinal diseases.